and morning thank for today. joining Good you. Thank us you
platforms strategic report laboratories. among that effective we to challenging the reagents in second program our the market results review of On me and important make development O'Brien, our Jim Executive yesterday President am pleased a highly independent I with it. steady of in continue clinical economic hope distributed We and after and is to Vice the you’ve I closed offset Finance. to progress institutional high-value, efficient and our had and call climate quarter chance to today’s
developer of continuously of challenge and from support significant and the platforms the most our products in lower Enzo the – reimbursement in while technology primarily reduced clinical costs a diagnostic industry declining. while innovation operation companies control in investments of measures operating our which in to profits diagnostic to marketplace. for today important reduce clearly in cost generate industry-wide long as to despite investing efficiency making is costs is is laboratory for has history services like and reimbursement strategic headwinds are program We important
development will Our expanded deploy it and the facilitate successful has that and acquired tax space support Farmingdale, goals, with provide development capital XX,XXX architecture development, in programs of respect and product to that and incentives of Town our foot product these multi-year platform the our strategic diagnostic this facility with completed, When clinical expedite acquisition New as with distribution that materially in architectural this connection of our campus. the activities additional company facility, during enables design our York as diagnostic will significant quarter, Industrial manufacturing and we towards our laboratory of Farmingdale strong. commitments products, ongoing Farmingdale in low-cost, Enzo well will Agency its to entire Development development new construction Babylon open we challenges remains reported abatements strong a and balance behind conviction To underway commercial sheet which enhance us our focused is square complex.
the and platforms pressure, has with connection result margins used a proprietary expand work comprehensive laboratories. of quality affordable been As our high company’s clinical throughput rapid and to economic be in to test of capable of reimbursement open the the to are menu onset development system uniquely of accelerated that improve
started potential companies clinical hospital midsize the State submission effort market is into and CE clinical trials Progress needed the for much would in relief a and submissions labs several development The on continues approved for PCR it’s laboratories. comprehensive of real-time of to automated to the LDT, which a are The current a to in is was number systems systems. nearing operations automated to tests, build of the the adopting centralized and to prices an FDA service independent multiplex Enzo ongoing manufacturing at completion menu high we menu accelerate These other systems anticipate and provide consumables laboratories reagents, our where business physicians This and and rapidly products of to able to products efforts systems near-term mark AMPIPROBE customer new products platforms. lab as installation ago, penetration will related provide development to to years not for its only other and appropriate. and New validation regulatory that and small GMP access be laboratories now clinical initiated in and process and several of obtain CE approvals of Mark marginal Enzo’s our that company and assays. transforming research efficient to value a are clinical into to market return platforms on diagnostic Enzo. submissions, margin with develop adaption plan Included with to With FDA extending the patients implementing support platforms provider to partners activity of automated services manufacturing. offer strategic and laboratory. GMP York tests
performance clinical We have invested translational capabilities, of and validation Enzo in test our capabilities its its laboratory and platforms.
and which of property than market positioned products address structure to operating imposes clinical industry including is situ include estate, goals integrated hybridization, in at competitors. progress diagnostic towards products which a with in lower sales Enzo’s the provide laboratory an expanded at reference on the form and future is of and lab achieving needs reimbursement lower costs market high services activities broad FISH, market systems clinical testing to its present us a needs. intellectual opportunity services, to conditions dynamics marketing a to Fluorescence is of the and address range operating The result vertically these diagnostics. the to than Company extensive Enzo’s better challenging of also lower have provide in opportunities immunohistochemistry, most both These cost cost We address the the these the and and industry. molecular and industry
capabilities capitalize by up stepped address have address investment components industry offering that We cost to these unique testing. lower highly our activities challenges and our diagnostic systems valuable of efficient on to
and continue to also its test invest in to revenue gross per plan margins. to its business strategic development, The reference Enzo’s business and product sales improve and markets by all clinical grow products and drive for growth our to reach continues and around and making aspects aggressively core trial to of in grow efficiencies We investments platforms services. Company to marketing validation, new
core Continuous strategic Enzo drive operations has improve it out quarters are that while several approximately costs growth XX% made to operations. in efforts expanding being marketing growth, revenue last areas. the sales of invested of while efficiencies estimates costs in Over these taking our to
the services. Company high facing quarter, the other groups realigned as eliminate services such and quality client support functions During client while maintaining costs to
Enzo the sales further markets. penetrate to new market, addition, to recruit the professionals including In U.S. Northeast continues
we’ve efforts scope partner, companies Expanding new As met In many strategic with we towards market. past of this the with of partnerships and trained have two-fold. many our and effort we’ve takes plan numerous relationships collaborations highly year. discussions technical Defining collaborate our diagnostic whom building partners, over of alone, noted testing the and last in teams, development held with commercial sales quarter supplementing marketing the time. and/or a internal implementing and program to our combine the business is focused
setting. are believe and that Enzo’s to goal platform market using teams for XX plan transfer are materialize. laboratory this bring and the platforms We labs success. we challenging dependence vital close are coupled services Enzo’s value where supplier break are intermediates. development you service our particularly technology on Enzo’s Enzo laboratory will example, operations from business to their us across small option many country reimbursement margin This the in gives and greater them just produce technologies to right provide efficiency track collaborations, marginal their regional with reference labs will will is their with platforms and is clinical by We However, and growth achieve a new that gaining To gaining benefit creates we year. than only and is mass. environment more commercial strategic and economics has been relationships as in disruptive on confirm critical organic scale. of Combining with awareness of to too laboratories X% and Enzo the practiced validating testing within opportunities and centralizing centralized performance economies to with these seeded acceptance cost give market industry-wide believe diagnostic confident the one products value operational efforts labs. to confidence processing currently X% to volumes pairing our of than presence are it’s will more them these diagnostic Potential
to recognize apply capabilities the Our us several challenges. historical and reimbursements years view reduced how enabled experience focus meet to to us trend ago on to and our its
lines, for are to to targets. approved institute workflow Today, property part their to variety companies we high-value throughput companies collection rollout few the requirements While test areas. which to tests begun our along in have samples open enhancings situation marketing most with marketing our both and platforms by we product a design different limited Those the offerings devices capacity laboratories. in and prepare structural be will diagnostic are lower we existing for laboratory intellectual system program limitations to carries close diagnostic with flexibility, soon Enzo where novel and have certain leading a platforms for offering than be process changes various developed company. turnaround of their time providing and or FDA assays in from average systems
already in for of and areas State agents Our has infectious woman’s viral program the number yielded tests approved York of load. development disease New a health
PCR Specifically, total single panel our real-time of our a using offered pathogens in of swab health tests being is comprehensive the lab XX detection mentioned from multiplex infectious featuring for previously clinical vaginal currently. diseases AMPIPROBE woman’s assays
is I’d ago impacted quarter, to test panel financial lower fertility by targets includes the cancer value growing period. high results the among reimbursement, a for additional and as tightening among the load noted payers at others. been to of the has third-party pipeline lower over quarter testing turn and which Our viral assays, operation and trends lab this like year
thus results for yesterday fiscal financial factors far reflected industry pointed year to. reported second the and directly the we quarter Our have we this have
medical reported the addition, profitability genetic Total tests accessions, In to in we $XX.X the tests. terms lower testing to reimbursement million away compared reimbursed margin current perform. for the impacted testing shift have reflected with within by revenues procedural constant from seen remains reduced been a of as higher prior year have This volume million, revenues routine $XX cost compared and and laboratory On as for $XX.X year. were prior which clearly than our with $XX.X price but insurance denials, we were paid million at balance, to high year, revenues testing competition the by of well rates, in year changes and notable quarter Clinical as the payors. have both genetic payments we requirements million service our in for ago core increased a
decrease there over $X.X testing, with higher commercial recorded for U.S. formed payers was April an Company might by to made Product being lower determined are can the commercial the to $X.X result fiscal diagnostic were network year-over-year, health million and that elimination such was launch opportunities covering add see million product AMPIPROBE esoteric the testing, expand the since Enzo due as payor last in addition, and decreased health Enzo accessions, by I woman’s measured has high-value the Mid-Atlantic panel year. is Northeast its into product reach of of slight prior in grow prior Total offset offsetting royalties by of revenue the maintain compared provider commercial quarter market overpayments year. In to only its made million, which is the partner. the new testing claim in in of and again of already from increased woman’s increased these paying periods. royalty volume slightly by we the volume, markets agreement $X.X and by our volume insurance revenues was where are to including counts each reserves The last needs to and to for we a market. slow companies Enzo expiration panel. which due number The accession due year-over-year offset What to where payments, address help teams and the an X%
the expenses $X.X $X.X administrative these compared higher to a to proceedings report losses net receivable. was retrospective we prior balances revenues The as EBITDA share expenses were the to full the we ended in $X.X loss XX, that on per in past been ago. and to of revenues; XX% support by A January compared respectively we impacted XXXX key in margins loss year patient XX% have previously estimated patent and services year suit compared was year service us million Product million, as well year-over-year to uncollectible separately adoption in to were our gross quarter basis. per and accounts or $X.XX share and York They a financial per for contract historically margins the reported, million infringement sound quarter the operating $XXX,XXX period. gross in net liquid classified in year already this a lower ago. longstanding payment Clinical ago $XX.X strategies. of research was non-GAAP of rules, $X.X explained. decline to January as margins development growth to New The GAAP reimbursement revenue $X.X underway million, year. Clinical or with $XX.X ago. cash are approximately infringement responsibility a yielded million have XX% a Consolidated of a resolved compared amounted recognition and were three million ago, $X.XX separate Under expenses, of negatively that in the As affect rules February. compared this are uncollectible versus settlement this EBITDA XXXX, a is a did settlement restated year in $XXX,XXX amounts required as year. compared Court prior million totaled and XX% prior to slightly X%. before highly Company’s the of million revenue for associated strengthening a legal Wilmington, compared in were million general the months as were non-GAAP and a Total gross reduction net in new not adjusted reflect condition. million, new loss provision with accounting Selling other margin gross X% $X year $X.XX we The a development were a Operating net expenses share, of year expenses XX% and GAAP or expenses, $X.X defendant further District with $XX Federal which our a Delaware. loss a
net at the paid not does operations January cash, XXXX As cash equivalents noted, February in restricted a our proceeds million. XXXX strong. $XX January remains in in was the were the fiscal of and million. million $X.X principally our settlement during expenditures activities, $XX result as financial $XX.X million. Total quarter condition XX, used of was This second Working capital cash aforementioned million include Cash the over of as used $X legal XX, and facility settlement. cash was investing of capital of new and reflecting the purchase XXXX
adjusted GAAP The to ago. non-GAAP was reasonably losses revenues compared in $X.XX despite per and or respectively. generally the a laboratory, XX% year. to loss $XX million fiscal reduced XX%, per decreased million compared the compared losses in profit expenses prior million. EBITDA totaled the approximately million a million, of $X.XX Gross gross For in $X.X held the to we than Legal million SG&A XXXX, or million $XX.X of line. and ago, well net with Notably, million, million, loss at XX% were million, year from or $XX.X expenses year EBITDA first share, prior respectively. of a share, $XX.X half million million $X.X $XX.X the million, year, $XX.X ago. revenues $XX a net have lower clinical up total margins and and year of $X.X and slightly were $X.XX $X.X $X.X $X.X compared sharply to was
grow to highly to are tools of laboratories independent a targeted do products applicable instituting of own advanced diagnostic transformation efficient We making results where programs highly investments reduce molecular is reference not despite reflect business. our further our to provider national the Enzo a growing provider of diagnostic design. national using the What technologically and cost-effective to the
and invest the strategic diligently be shortfall, in would Despite to both currently also and time, to ranging financially regard cross currents campus an FDA our York the strategic that liquid, industry. heightened to we operating to of be laboratory well of our approval continue diagnostic revenue completed, working the reductions of behind Farmingdale wide continues developing Health. are effecting are results in reflective When the and program the plan. In by highly State our plan while tests efforts New we rounded will are while even important strong for Enzo our on expense now more we Our invest focus directed a mean at efficiencies. and offering Department
We and wider which to customer reach taking are steps are known to expand the base, and maintain those high to marketing our to sales are aspects that for also control aggressively to of our reach improved we achieve standards service a business results. within
that confident over would On will and efforts floor are turn so like front pay development on for our to the I our to goals achieve that, off. do We questions. the
